🧾 What This Document Is

This is an 8-K filing from Forte Biosciences, which is essentially a press release they sent to investors and the SEC. It's announcing their full-year 2025 financial results and giving an update on their drug development progress. Think of it as a company's "state of the union" for the past year and a preview of what's coming next.

🏢 What The Company Does

👉 In simple terms, Forte Biosciences is a biotech company that doesn't sell any medicines yet. They are in the research and development (R&D) stage, trying to create new drugs for autoimmune diseases like celiac disease, vitiligo, and alopecia areata. Their main hope is a drug candidate called FB102.

📈 Financial Highlights

The company is spending heavily to develop its drug, which is typical for a clinical-stage biotech.

• Research & Development (R&D) Expenses: Jumped to $58.2 million in 2025 from $21.2 million in 2024. This is the cost of running clinical trials.
• Net Loss: Their annual loss widened to $69.4 million in 2025 from $35.5 million in 2024. This loss is the net result of all their spending.
• Cash on Hand: They ended 2025 with a much stronger cash position of $77.0 million, up from $22.2 million at the end of 2024. This extra cash is fuel for their upcoming trials.

🚀 Key Moves & Clinical Progress

The big story is all about their lead drug, FB102. The company is running multiple clinical trials and expects important results in 2026.

• Celiac Disease: A Phase 2 study is ongoing. They expect topline results in 2026, building on positive Phase 1b results from June 2025.
• Vitiligo: A Phase 1b study is expected to report results in the first half of 2026.
• Alopecia Areata: Another Phase 1b study data readout is expected sometime in 2026. 👉 Why it matters: 2026 is a make-or-break year. Positive data from these trials could validate FB102 and dramatically increase the company's value.

💸 The Cash Flow Story

The financial statements show where the money went and where it came from.

• Burning Cash on R&D: The massive increase in R&D spending (a $36 million jump) was mainly for manufacturing and clinical trial costs for FB102. This is a planned investment.
• Raising Capital: The huge increase in cash (from $22.2M to $77.0M) and the jump in "Additional paid-in capital" on the balance sheet (from $206.5M to $284.3M) strongly suggest the company raised money from investors during 2025 to fund this expensive research phase.

🔮 What's Next

Management calls 2026 a "very eventful year." The entire focus is on executing the FB102 clinical trials and delivering the data readouts. The upcoming results will determine if the drug has "potential to address... multi-billion dollar market opportunities."

⚖️ Big Picture: Strengths & Risks

• 👍 Strengths: A promising drug pipeline (FB102) targeting large disease markets; positive early Phase 1b results; a well-funded cash runway to run the critical trials.
• ⚠️ Risks: As a clinical-stage company, its success is almost entirely dependent on clinical trial outcomes, which are risky and uncertain. It has no product revenue and continues to burn significant cash each year. Any negative trial result could be devastating.

🧠 The Analogy

Forte Biosciences is like a startup building a Swiss Army knife (FB102). They've built the basic tools (positive Phase 1b data) and now they're testing each one in real-world situations (Phase 2/1b trials for different diseases) in 2026. If the celiac, vitiligo, and alopecia tools all work well, they'll have a massively valuable product. If the main blade breaks, the whole project could fail.

📇 Key Contacts & People

• Paul Wagner, PhD: CEO
• Mike Moyer: Managing Director at LifeSci Advisors (Investor Relations)
• Emails: [email protected], [email protected]

🧩 Final Takeaway

Forte Biosciences spent a lot of money in 2025 to prepare for a critical 2026. They raised significant cash and now have the resources to test their lead drug, FB102, in multiple diseases. The company's entire future hinges on the clinical trial results expected this year.